Tessera Therapeutics
Xijia W. currently serves as a Senior Research Associate at Tessera Therapeutics, where responsibilities include supporting the development of novel gene editors and conducting proof-of-concept studies involving cancer and primary cell lines. Previously, Xijia W. worked as a Research Associate at AGTC, contributing to a pre-clinical gene therapy project aimed at developing precision treatments for ALS and optimizing HSV-based AAV production. Xijia W. holds a Bachelor's degree in Biotechnology from Sun Yat-sen University and a Master of Engineering in Bioengineering and Biomedical Engineering from Cornell University, and is currently pursuing a Master's degree in Regulatory Affairs at Northeastern University.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.